Park Hotels & Resorts Inc. Common Stock vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Park Hotels & Resorts Inc. Common Stock trades at $15.12 (market cap $3.14B), while Royalty Pharma plc Class A Ordinary Shares trades at $59.03 (market cap $25.18B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 8× Park Hotels & Resorts Inc. Common Stock's market cap, and Park Hotels & Resorts Inc. Common Stock pays the higher dividend (6.41%). Which is the better fit depends on your goals — on Pluang, investors hold Park Hotels & Resorts Inc. Common Stock for 0 Days and Royalty Pharma plc Class A Ordinary Shares for 6 Days on average.
| PK | RPRX | |
|---|---|---|
Market Cap | $3.14B | $25.18B |
Volume | 3,553,985 | 3,399,248 |
Sector | Real Estate | Health |
52-Week High | $16.17 | $63.96 |
52-Week Low | $9.84 | $36.18 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $6.98B | $32.42B |
Dividend Yield | 6.41% | 1.66% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Royalty Pharma (RPRX) trades at $56.57, down 2.09% on the day, with a bullish technical signal and strong fundamentals. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue and net income show steady growth, supported by a high gross profit margin of 89.38%. Analyst consensus is unanimously bullish with a $63.33 price target.
The outlook remains positive given earnings momentum and strategic capital deployment, though risks include biopharma policy shifts and reliance on partner drug performance. The stock offers exposure to a diversified portfolio of blockbuster drugs with minimal operational risk, but investors should monitor upcoming earnings and broader sector dynamics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Park Hotels & Resorts Inc. is a US lodging REIT, spun off from Hilton Worldwide in 2017, that owns a portfolio of premium-branded hotels and resorts in major urban, resort, and convention markets.
Read more on PK →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →